LQDA

Liquidia Resubmits New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension

Liquidia Announces Generic Treprostinil Injection Will Be Available for Subcutaneous Route of Administration

Liquidia Technologies, Inc. (LQDA) CEO Damian deGoa on Q4 2020 Results - Earnings Call Transcript

Liquidia Corporation to Host 2020 Financial Results Conference Call on March 23, 2021

Liquidia Corporation Secures $20.5 Million Debt Facility with Silicon Valley Bank

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Liquidia Corporation and Encourages Investors with Losses of $100,000 to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Liquidia Corporation and Encourages Investors with Losses of $100,000 to Contact the Firm